Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients

Part of paid clinical trials in Houston, Texas.

Sponsor
Theolytics Limited
Study ID
NCT07211659
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • THEO-260 — BIOLOGICAL
    Oncolytic virus

Study Details

A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered by the intraperitoneal route to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumour activity.

Key Dates

Start date
Feb 13, 2026
Status verified
Apr 2026
Primary completion
Sep 30, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
18 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: THEO-260

Primary Outcome Measure

Safety and tolerability of THEO-260 [ Time Frame: Until Day 28 after first dose ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Amir Jazaeri, MD
[email protected]
+1 (713) 745-1613
Amir Jazaeri (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
MD Anderson Cancer Center· Houston, TX

Related Studies